This Human GIP overexpression lysate was created in HEK293 Cells and intented for use as a Western blot (WB) positive control. Purification of GIP protein (Cat: 15340-H02H) from the overexpression lysate was verified.
A DNA sequence encoding the human GIP (NP_004114.1) (Met1-Gln93) was expressed with the Fc region of human IgG1 at the C-terminus.
The recombinant human GIP consists 310 amino acids and predicts a molecular mass of 34.9 kDa.
Human GIP HEK293 Overexpression Lysate: 使用指南
Cell lysate was prepared by homogenization of the over-expressed cells in ice-cold modified RIPA Lysis Buffer with cocktail of protease inhibitors (Sigma). Cell debris was removed by centrifugation. Protein concentration was determined by Bradford assay (Bio-Rad protein assay, Microplate Standard assay). The cell lysate was boiled for 5 min in 1 x SDS loading buffer (50 mM Tris-HCl pH 6.8, 12.5% glycerol, 1% sodium dodecylsulfate, 0.01% bromophenol blue) containing 5% b-mercaptoethanol, and lyophilized.
1. Centrifuge the tube for a few seconds and ensure the pellet at the bottom of the tube.
2. Re-dissolve the pellet using 200μL pure water and boil for 2-5 min.
1 X Sample Buffer (1 X modified RIPA buffer+1 X SDS loading buffer).
稳定性 & 储存条件
Store at 4℃ for up to twelve months from date of receipt. After re-dissolution, aliquot and store at -80℃ for up to twelve months. Avoid repeated freeze-thaw cycles.
Western Blot (WB) Optimal dilutions/concentrations should be determined by the end user.
Human GIP HEK293 Overexpression Lysate: 别称
Human GIP Overexpression Lysate
Glucose-dependent insulinotropic polypeptide (GIP) is an incretin that plays an important role in fat accumulation. GIP is involved in fat accumulation and insulin resistance with aging. Glucose-dependent insulinotropic polypeptide (GIP) is an intestinal hormone with a broad range of physiological actions. Elevated concentrations of the incretin hormone GIP are found in patients with atherosclerotic cardiovascular disease, while GIP treatment attenuates atherosclerotic plaque inflammation in mice and abrogates inflammatory macrophage activation in vitro. That GIP as a counterregulatory vasoprotective peptide, which might open new therapeutic avenues for the treatment of patients with high cardiovascular risk.